CERS - Cerus Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.02
+0.02 (+0.67%)
As of 11:00AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.00
Open3.04
Bid3.01 x 1200
Ask3.02 x 1200
Day's Range2.99 - 3.04
52 Week Range1.93 - 5.91
Volume209,152
Avg. Volume935,467
Market Cap329.6M
Beta1.34
PE Ratio (TTM)-4.93
EPS (TTM)-0.61
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.33
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Cerus to Release Third Quarter 2017 Results on November 2, 2017

    Cerus Corporation announced today that its third quarter results will be released on Thursday, November 2, 2017, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the company’s financial results and provide a general business overview and outlook.

  • Capital Cube4 days ago

    ETFs with exposure to Cerus Corp. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cerus Corp. Here are 5 ETFs with the largest exposure to CERS-US. Comparing the performance and risk of Cerus Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Cerus Corporation (CERS) Looks Good: Stock Adds 8.2% in Session
    Zacks14 days ago

    Cerus Corporation (CERS) Looks Good: Stock Adds 8.2% in Session

    Cerus Corporation (CERS) saw its shares rise over 8% on the day on the back of the news of a favorable regulatory development.

  • Why Cerus Corporation Stock Marched Higher Today
    Motley Fool15 days ago

    Why Cerus Corporation Stock Marched Higher Today

    A positive regulatory development sent Cerus' shares higher today.

  • Business Wire15 days ago

    Cerus Announces First Biologics License Application Approval for U.S. Blood Center Customer

    Cerus Corporation announced today that Rhode Island Blood Center received approval by the U.S. Food and Drug Administration on their Biologics License Application requesting allowance for interstate distribution of platelets that have been pathogen-reduced with the INTERCEPT Blood System.

  • Capital Cube17 days ago

    ETFs with exposure to Cerus Corp. : October 3, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cerus Corp. Here are 5 ETFs with the largest exposure to CERS-US. Comparing the performance and risk of Cerus Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube28 days ago

    ETFs with exposure to Cerus Corp. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cerus Corp. Here are 5 ETFs with the largest exposure to CERS-US. Comparing the performance and risk of Cerus Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Cerus Corp. :CERS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
    Capital Cube29 days ago

    Cerus Corp. :CERS-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017

    Categories: Yahoo FinanceGet free summary analysis Cerus Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Cerus Corp. – Haemonetics Corporation, Cytori Therapeutics, Inc., Teligent, Inc., Vical Incorporated, Cesca Therapeutics Inc. and BioTime, Inc. (HAE-US, CYTX-US, TLGT-US, VICL-US, KOOL-US and BTX-US) that have also reported ... Read more (Read more...)

  • Business Wirelast month

    Cerus to Present at Cantor Fitzgerald’s Annual Healthcare Conference on September 27, 2017

    Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cantor Fitzgerald Healthcare Conference at 10:20 AM ET on Wednesday, September 27, 2017.

  • Business Wire2 months ago

    Cerus to Present at Two Upcoming Conferences

    Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, will present at two upcoming conferences:

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CERS earnings conference call or presentation 3-Aug-17 8:15pm GMT

    Q2 2017 Cerus Corp Earnings Call

  • Associated Press3 months ago

    Cerus reports 2Q loss

    On a per-share basis, the Concord, California-based company said it had a loss of 16 cents. The biomedical products company posted revenue of $9.5 million in the period. Cerus expects full-year revenue ...

  • Business Wire3 months ago

    Cerus Corporation Reports Second Quarter 2017 Results

    Cerus Corporation today announced financial results for the second quarter ended June 30, 2017.

  • ACCESSWIRE3 months ago

    Investor Network: Cerus Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 3, 2017 / Cerus Corporation (NASDAQ: CERS ) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:15 PM Eastern ...

  • Business Wire3 months ago

    Cerus Enters Into $40 Million Amended Growth Capital Agreement

    Cerus Corporation announced today that it has entered into a $40 million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide.

  • Business Wire3 months ago

    Cerus Announces Expanded Supply Agreement with French National Blood Service

    Cerus Corporation announced today the signing of two, new, expanded contracts with Établissement Français du Sang , the French National Blood Service, for the INTERCEPT Blood System.

  • ACCESSWIRE3 months ago

    LD Micro Index Reconstitution as of August 1, 2017

    LOS ANGELES, CA / ACCESSWIRE / August 01, 2017 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of August 1, 2017. We believe that the existence of a true micro-cap index, ...

  • Business Wire3 months ago

    Cerus Announces Collaboration with Central California Blood Center to Manufacture Pathogen-Reduced Cryoprecipitate

    Cerus Corporation announced today an agreement with the Central California Blood Center in which CCBC will manufacture pathogen-reduced cryoprecipitate for the company.

  • Business Wire3 months ago

    Cerus to Release Second Quarter 2017 Results on August 3, 2017

    Cerus Corporation announced today that its second quarter results will be released on Thursday, August 3, 2017, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

  • Capital Cube3 months ago

    ETFs with exposure to Cerus Corp. : July 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cerus Corp. Here are 5 ETFs with the largest exposure to CERS-US. Comparing the performance and risk of Cerus Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Business Wire4 months ago

    INTERCEPT Blood System Highlighted at the International Society of Blood Transfusion (ISBT)

    Cerus Corporation announced results of 16 abstracts presenting experiences with the INTERCEPT Blood System for platelets, plasma, and red blood cells during the 27th Regional Congress of the International Society of Blood Transfusion in Copenhagen, Denmark held from June 17 to June 21, 2017.

  • Accesswire4 months ago

    Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation

    NEW YORK, NY / ACCESSWIRE / June 8, 2017 / Calithera Biosciences scored a big win on Wednesday after the FDA granted it Fast Track Designation on its cancer treatment CB-839. Cerus Corporation's shares ...

  • Here's Why Cerus Corporation Rose as Much as 17.4% Today
    Motley Fool4 months ago

    Here's Why Cerus Corporation Rose as Much as 17.4% Today

    The company provided an update on the most pressing issue facing the biopharma stock in 2017.

  • Business Wire4 months ago

    Cerus Provides Update on U.S. Platelet Additive Solution (PAS) Supply

    Cerus Corporation announced today that the expected Fresenius Kabi platelet additive solution shortage the company announced on May 23, 2017, could be less disruptive to blood center production of INTERCEPT platelets than initially anticipated.